{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:20:18Z","timestamp":1793701218662,"version":"4.5.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA97274"],"award-info":[{"award-number":["CA97274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA212162-01A1"],"award-info":[{"award-number":["CA212162-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA195568"],"award-info":[{"award-number":["CA195568"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-50830-y","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:03:06Z","timestamp":1723158186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation"],"prefix":"10.1038","volume":"15","author":[{"given":"Matthew E.","family":"Stokes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Wenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1116-2756","authenticated-orcid":false,"given":"C. Chris","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0678-637X","authenticated-orcid":false,"given":"Nicholas","family":"Stong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-1519","authenticated-orcid":false,"given":"Yumi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-0553","authenticated-orcid":false,"given":"Hsiling","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Polonskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Danziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Towfic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4712","authenticated-orcid":false,"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekananda","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan W.","family":"Asmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sudhindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-9132","authenticated-orcid":false,"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Hagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7904-1651","authenticated-orcid":false,"given":"Anne J.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"50830_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras, L. R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. Cancer J. Clin. 66, 443\u2013459 (2016).","journal-title":"Cancer J. Clin."},{"key":"50830_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"L Sehn","year":"2021","unstructured":"Sehn, L. & Salles, G. Diffuse large B-cell lymphoma. N. Engl. J. Med. 384, 842\u2013858 (2021).","journal-title":"N. Engl. J. Med."},{"key":"50830_CR3","first-page":"2060","volume":"131","author":"DW Scott","year":"2018","unstructured":"Scott, D. W. et al. High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. J. Am. Soc. Hematol. 131, 2060\u20132064 (2018).","journal-title":"J. Am. Soc. Hematol."},{"key":"50830_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"50830_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski, G. S. et al. ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J. Clin. Oncol. 39, 1317 (2021).","journal-title":"J. Clin. Oncol."},{"key":"50830_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes, A. et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma. J. Clin. Oncol. 37, 1285 (2019).","journal-title":"J. Clin. Oncol."},{"key":"50830_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690 (2018).","journal-title":"Nat. Med."},{"key":"50830_CR8","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396\u20131407 (2018).","journal-title":"N. Engl. J. Med."},{"key":"50830_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright, G. W. et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37, 551\u2013568 (2020).","journal-title":"Cancer Cell"},{"key":"50830_CR10","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy, S. E. et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood 135, 1759\u20131771 (2020).","journal-title":"Blood"},{"key":"50830_CR11","first-page":"2493","volume":"141","author":"W Alduaij","year":"2023","unstructured":"Alduaij, W. et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood 141, 2493\u20132507 (2023).","journal-title":"Blood"},{"key":"50830_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.18.01583","volume":"37","author":"D Ennishi","year":"2019","unstructured":"Ennishi, D. et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J. Clin. Oncol. 37, 190 (2019).","journal-title":"J. Clin. Oncol."},{"key":"50830_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.18.01314","volume":"37","author":"C Sha","year":"2019","unstructured":"Sha, C. et al. Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J. Clin. Oncol. 37, 202 (2019).","journal-title":"J. Clin. Oncol."},{"key":"50830_CR14","first-page":"1008","volume":"135","author":"A Risue\u00f1o","year":"2020","unstructured":"Risue\u00f1o, A. et al. Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent. Blood 135, 1008\u20131018 (2020).","journal-title":"Blood"},{"key":"50830_CR15","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov, N. et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 11, 1468\u20131489 (2021).","journal-title":"Cancer Discov."},{"key":"50830_CR16","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen, C. B. et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell 39, 1422\u20131437 (2021).","journal-title":"Cancer Cell"},{"key":"50830_CR17","doi-asserted-by":"crossref","unstructured":"Zhang, M. C. et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial. Cancer Cell. 41, 1705\u20131716.e5 (2023).","DOI":"10.1016\/j.ccell.2023.09.004"},{"key":"50830_CR18","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.3390\/cancers13246168","volume":"13","author":"Q Mo","year":"2021","unstructured":"Mo, Q. et al. Integrative analysis identifies multi-omics signatures that drive molecular classification of uveal melanoma. Cancers 13, 6168 (2021).","journal-title":"Cancers"},{"key":"50830_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 1\u201315 (2013).","journal-title":"BMC Bioinform."},{"key":"50830_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy, A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171, 481\u2013494 (2017).","journal-title":"Cell"},{"key":"50830_CR21","doi-asserted-by":"crossref","unstructured":"Wallden, B. et al. Development of the molecular diagnostic (MDx) DLBCL lymphoma subtyping test (LST) on the nCounter analysis system. J. Clin. Oncol. 33 (2015).","DOI":"10.1200\/jco.2015.33.15_suppl.8536"},{"key":"50830_CR22","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/ije\/dyx119","volume":"46","author":"JR Cerhan","year":"2017","unstructured":"Cerhan, J. R. et al. Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study. Int. J. Epidemiol. 46, 1753\u20131754i (2017).","journal-title":"Int. J. Epidemiol."},{"key":"50830_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies, A. et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 20, 649\u2013662 (2019).","journal-title":"Lancet Oncol."},{"key":"50830_CR24","first-page":"351","volume":"386","author":"U Vitolo","year":"2017","unstructured":"Vitolo, U. et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J. Clin. Oncol. 386, 351 (2017).","journal-title":"J. Clin. Oncol."},{"key":"50830_CR25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer, M. J. et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 32, 1066 (2014).","journal-title":"J. Clin. Oncol."},{"key":"50830_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41375-023-02120-7","volume":"38","author":"WW Ren","year":"2024","unstructured":"Ren, W. W. et al. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis. Leukemia 38, 610\u2013620 (2024).","journal-title":"Leukemia"},{"key":"50830_CR27","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2022-159620","volume":"140","author":"K Wenzl","year":"2022","unstructured":"Wenzl, K. et al. Integrative genomics identifies a high-risk metabolic and TME depleted signature that predicts early clinical failure in DLBCL. Blood 140, 1742\u20131744 (2022).","journal-title":"Blood"},{"key":"50830_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01080-0","volume":"14","author":"K Wenzl","year":"2024","unstructured":"Wenzl, K. et al. Multiomic analysis identifies a high-risk metabolic and TME depleted signature that predicts early clinical failure in DLBCL. Blood Cancer J. 14, 100 (2024).","journal-title":"Blood Cancer J."},{"key":"50830_CR29","doi-asserted-by":"publisher","first-page":"eaav5599","DOI":"10.1126\/scitranslmed.aav5599","volume":"11","author":"N Jain","year":"2019","unstructured":"Jain, N. et al. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci. Transl. Med. 11, eaav5599 (2019).","journal-title":"Sci. Transl. Med."},{"key":"50830_CR30","doi-asserted-by":"publisher","first-page":"6840","DOI":"10.4049\/jimmunol.178.11.6840","volume":"178","author":"KG Elpek","year":"2007","unstructured":"Elpek, K. G., Lacelle, C., Singh, N. P., Yolcu, E. S. & Shirwan, H. CD4+ CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178, 6840\u20136848 (2007).","journal-title":"J. Immunol."},{"key":"50830_CR31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.4049\/jimmunol.1402382","volume":"194","author":"JM God","year":"2015","unstructured":"God, J. M. et al. Elevation of c-MYC disrupts HLA class II\u2013mediated immune recognition of human B cell tumors. J. Immunol. 194, 1434\u20131445 (2015).","journal-title":"J. Immunol."},{"key":"50830_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 1\u201319 (2021).","journal-title":"Nat. Commun."},{"key":"50830_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co\u2010stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN. Br. J. Haematol. 164, 811\u2013821 (2014).","journal-title":"Br. J. Haematol."},{"key":"50830_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/156800910791054239","volume":"10","author":"A Gandhi","year":"2010","unstructured":"Gandhi, A. et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr. Cancer Drug Targets 10, 155\u2013167 (2010).","journal-title":"Curr. Cancer Drug Targets"},{"key":"50830_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"50830_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","volume":"126","author":"PR Hagner","year":"2015","unstructured":"Hagner, P. R. et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood 126, 779\u2013789 (2015).","journal-title":"Blood"},{"key":"50830_CR37","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1158\/1078-0432.CCR-21-3347","volume":"28","author":"PR Hagner","year":"2022","unstructured":"Hagner, P. R. et al. Interactome of Aiolos\/Ikaros reveals combination rationale of cereblon modulators with HDAC inhibitors in DLBCL. Clin. Cancer Res. 28, 3367\u20133377 (2022).","journal-title":"Clin. Cancer Res."},{"key":"50830_CR38","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood.2019002395","volume":"135","author":"CB Carpio","year":"2020","unstructured":"Carpio, C. B. et al. Avadomide monotherapy in relapsed\/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood 135, 996\u20131007 (2020).","journal-title":"Blood"},{"key":"50830_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-022-00923-8","volume":"8","author":"K Jiang","year":"2022","unstructured":"Jiang, K. et al. MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40\/CD40L system in osteosarcoma. Cell Death Discov. 8, 1\u201312 (2022).","journal-title":"Cell Death Discov."},{"key":"50830_CR40","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/modpathol.2015.118","volume":"28","author":"ZY Xu-Monette","year":"2015","unstructured":"Xu-Monette, Z. Y. et al. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod. Pathol. 28, 1555\u20131573 (2015).","journal-title":"Mod. Pathol."},{"key":"50830_CR41","first-page":"2196","volume":"137","author":"B Collinge","year":"2021","unstructured":"Collinge, B. et al. The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood 137, 2196\u20132208 (2021).","journal-title":"Blood"},{"key":"50830_CR42","doi-asserted-by":"publisher","first-page":"584095","DOI":"10.3389\/fonc.2020.584095","volume":"10","author":"C Luciano","year":"2020","unstructured":"Luciano, C., Luca, A., Michael, B. & Francesco, B. DNA copy number changes in diffuse large B cell lymphomas. Front. Oncol. 10, 584095 (2020).","journal-title":"Front. Oncol."},{"key":"50830_CR43","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","volume":"22","author":"P Caro","year":"2012","unstructured":"Caro, P. et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22, 547\u2013560 (2012).","journal-title":"Cancer Cell"},{"key":"50830_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ccr.2012.07.014","volume":"22","author":"SC Monti","year":"2012","unstructured":"Monti, S. C. et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 22, 359\u2013372 (2012).","journal-title":"Cancer Cell"},{"key":"50830_CR45","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41375-020-0766-4","volume":"35","author":"KT Hartert","year":"2021","unstructured":"Hartert, K. T. et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia 35, 522\u2013533 (2021).","journal-title":"Leukemia"},{"key":"50830_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"50830_CR47","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","volume":"378","author":"ER Watson","year":"2022","unstructured":"Watson, E. R. et al. Molecular glue CELMoD compounds are regulators of cereblon conformation. Science 378, 549\u2013553 (2022).","journal-title":"Science"},{"key":"50830_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/bjh.14866","volume":"179","author":"P Hagner","year":"2017","unstructured":"Hagner, P. et al. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell\u2010mediated cytotoxicity. Br. J. Haematol. 179, 399\u2013409 (2017).","journal-title":"Br. J. Haematol."},{"key":"50830_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang, Y. et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer cell 21, 723\u2013737 (2012).","journal-title":"Cancer cell"},{"key":"50830_CR50","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","volume":"160","author":"LH Zhang","year":"2013","unstructured":"Zhang, L. H. et al. Lenalidomide efficacy in activated B\u2010cell\u2010like subtype diffuse large B\u2010cell lymphoma is dependent upon IRF 4 and cereblon expression. Br. J. Haematol. 160, 487\u2013502 (2013).","journal-title":"Br. J. Haematol."},{"key":"50830_CR51","doi-asserted-by":"crossref","unstructured":"Carrancio, S. et al. CC-99282 is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced tumoricidal activity in preclinical models of lymphoma. In: American Society of Hematology Annual Meeting. Atlanta, GA (2021).","DOI":"10.1182\/blood-2021-148068"},{"key":"50830_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly, H. et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N. Engl. J. Med. 386, 351\u2013363 (2022).","journal-title":"N. Engl. J. Med."},{"key":"50830_CR53","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","volume":"6","author":"AM Br\u00f6ske","year":"2022","unstructured":"Br\u00f6ske, A. M. et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma. Blood Adv. 6, 1025\u20131037 (2022).","journal-title":"Blood Adv."},{"key":"50830_CR54","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994\u20131007 (2012).","journal-title":"Cell"},{"key":"50830_CR55","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/nprot.2018.033","volume":"13","author":"Y Cun","year":"2018","unstructured":"Cun, Y., Yang, T. P., Achter, V., Lang, U. & Peifer, M. Copy-number analysis and inference of subclonal populations in cancer genomes using Sclust. Nat. Protoc. 13, 1488\u20131501 (2018).","journal-title":"Nat. Protoc."},{"key":"50830_CR56","doi-asserted-by":"crossref","unstructured":"Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M., & Alizadeh, A. A. Profiling tumor infiltrating immune cells with CIBERSORT. Cancer Syst. Biol. 1711, 243\u2013259 (2018).","DOI":"10.1007\/978-1-4939-7493-1_12"},{"key":"50830_CR57","doi-asserted-by":"publisher","first-page":"e0224693","DOI":"10.1371\/journal.pone.0224693","volume":"14","author":"SA Danziger","year":"2019","unstructured":"Danziger, S. A. et al. ADAPTS: Automated deconvolution augmentation of profiles for tissue specific cells. PLoS ONE 14, e0224693 (2019).","journal-title":"PLoS ONE"},{"key":"50830_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00382-3","volume":"10","author":"JE Krull","year":"2020","unstructured":"Krull, J. E. et al. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH\/TH DLBCL patients. Blood Cancer J. 10, 1\u20138 (2020).","journal-title":"Blood Cancer J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50830-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50830-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50830-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:02:39Z","timestamp":1723161759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50830-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50830"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50830-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"30 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.E.S., K.W., C.C.H., A.P., M.O., N.S., Y.N., C.H., L.W., H.C., A.S., P.H., and A.K.G. are employees and\/or stakeholders in BMS. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6790"}}